Venetoclax with Induction & Consolidation
A Phase II Randomized Clinical Trial of Venetoclax Combined With FLAG IDA Induction and Consolidation Compared to Standard of Care for Newly Diagnosed Patients With Acute Myeloid Leukemia
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 102 patients (estimated)
- Sponsors
- Oregon Health and Science University
- Tags
- BCL-2 Inhibitor, Pre-Allogeneic Stem Cell Transplant, Randomization
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2190
- NCT Identifier
- NCT07228273
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.